O-RADS for assessment of adnexal lesions: current status, challenges and future directions.

IF 4.8 2区 医学 Q2 ONCOLOGY
Yang Guo, Lori M Strachowski, Atul B Shinagare, Katherine E Maturen, Maitray D Patel, Elizabeth A Sadowski, Rochelle F Andreotti
{"title":"O-RADS for assessment of adnexal lesions: current status, challenges and future directions.","authors":"Yang Guo, Lori M Strachowski, Atul B Shinagare, Katherine E Maturen, Maitray D Patel, Elizabeth A Sadowski, Rochelle F Andreotti","doi":"10.1186/s40644-026-01061-5","DOIUrl":null,"url":null,"abstract":"<p><p>The Ovarian-Adnexal Reporting and Data System (O-RADS), developed by the American College of Radiology (ACR), provides a standardized, evidence-based framework for risk stratification and management of ovarian and adnexal lesions. The O-RADS system is comprised of two complementary imaging arms: ultrasound (US) and magnetic resonance imaging (MRI). O-RADS US serves as the primary imaging modality for adnexal lesion assessment, given its wide availability in outpatient and inpatient settings, relatively low cost, lack of ionizing radiation and the ability for real-time dynamic assessment. Using defined lexicon terms, lesions are stratified into five risk categories corresponding to an estimated malignancy risk with associated management recommendations. Validation studies have demonstrated high sensitivities for malignancy detection, good specificities, and strong interobserver agreement. The 2022 update refined selected descriptors to improve specificity while otherwise maintaining diagnostic performance and reproducibility, reinforcing the system's clinical utility. O-RADS MRI functions as a secondary, problem-solving tool for lesions that are technically limited or when MRI evaluation may add value. Validation studies have consistently shown excellent performance of O-RADS MRI with studies showing high specificities approaching 90-95% related to better characterization of solid tissue based on signal and dynamic enhancement characteristics. Together, O-RADS US and MRI establish a comprehensive, standardized approach that improves diagnostic confidence and optimizes patient management. Ongoing efforts focus on improving congruence between these two arms by addressing discrepancies, understanding and lowering barriers for adoption, and providing management recommendations for O-RADS MRI. Emerging evidence and evolving technologies, such as contrast-enhanced ultrasound (CEUS), quantitative imaging biomarkers and artificial intelligence (AI), may further advance the system. This review summarizes the background and validation of O-RADS US and O-RADS MRI, discusses their complementary roles, current challenges and barriers to adoption, and outlines future priorities and research directions.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13576368/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-026-01061-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The Ovarian-Adnexal Reporting and Data System (O-RADS), developed by the American College of Radiology (ACR), provides a standardized, evidence-based framework for risk stratification and management of ovarian and adnexal lesions. The O-RADS system is comprised of two complementary imaging arms: ultrasound (US) and magnetic resonance imaging (MRI). O-RADS US serves as the primary imaging modality for adnexal lesion assessment, given its wide availability in outpatient and inpatient settings, relatively low cost, lack of ionizing radiation and the ability for real-time dynamic assessment. Using defined lexicon terms, lesions are stratified into five risk categories corresponding to an estimated malignancy risk with associated management recommendations. Validation studies have demonstrated high sensitivities for malignancy detection, good specificities, and strong interobserver agreement. The 2022 update refined selected descriptors to improve specificity while otherwise maintaining diagnostic performance and reproducibility, reinforcing the system's clinical utility. O-RADS MRI functions as a secondary, problem-solving tool for lesions that are technically limited or when MRI evaluation may add value. Validation studies have consistently shown excellent performance of O-RADS MRI with studies showing high specificities approaching 90-95% related to better characterization of solid tissue based on signal and dynamic enhancement characteristics. Together, O-RADS US and MRI establish a comprehensive, standardized approach that improves diagnostic confidence and optimizes patient management. Ongoing efforts focus on improving congruence between these two arms by addressing discrepancies, understanding and lowering barriers for adoption, and providing management recommendations for O-RADS MRI. Emerging evidence and evolving technologies, such as contrast-enhanced ultrasound (CEUS), quantitative imaging biomarkers and artificial intelligence (AI), may further advance the system. This review summarizes the background and validation of O-RADS US and O-RADS MRI, discusses their complementary roles, current challenges and barriers to adoption, and outlines future priorities and research directions.

O-RADS用于附件病变评估:现状、挑战和未来方向。
由美国放射学会(ACR)开发的卵巢-附件报告和数据系统(O-RADS)为卵巢和附件病变的风险分层和管理提供了一个标准化的、基于证据的框架。O-RADS系统由两个互补的成像臂组成:超声(US)和磁共振成像(MRI)。O-RADS US作为附件病变评估的主要成像方式,因为它在门诊和住院环境中广泛可用,成本相对较低,缺乏电离辐射,能够进行实时动态评估。使用定义的词汇术语,病变被分为五个风险类别,对应于估计的恶性肿瘤风险和相关的管理建议。验证研究已经证明了恶性肿瘤检测的高敏感性,良好的特异性和强观察者间的一致性。2022年的更新改进了选定的描述符,以提高特异性,同时保持诊断性能和可重复性,加强了系统的临床实用性。O-RADS MRI作为次要的解决问题的工具,用于技术上有限的病变或当MRI评估可能增加价值时。验证研究一致表明,O-RADS MRI具有优异的性能,研究显示,基于信号和动态增强特性的实体组织更好的表征具有接近90-95%的高特异性。O-RADS US和MRI共同建立了全面、标准化的方法,提高了诊断信心并优化了患者管理。目前的工作重点是通过解决差异、理解和降低采用障碍,以及为O-RADS MRI提供管理建议,来改善这两个分支之间的一致性。新出现的证据和不断发展的技术,如对比增强超声(CEUS)、定量成像生物标志物和人工智能(AI),可能会进一步推动该系统的发展。本文综述了O-RADS US和O-RADS MRI的背景和验证,讨论了它们的互补作用、当前的挑战和采用障碍,并概述了未来的重点和研究方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Imaging
Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
7.00
自引率
0.00%
发文量
66
审稿时长
>12 weeks
期刊介绍: Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书